enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves first medication for obstructive sleep apnea ...

   www.aol.com/news/fda-approves-first-medication...

   The first medication for obstructive sleep apnea has been approved by the U.S. Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly's Zepbound ...

3. Solriamfetol - Wikipedia

   en.wikipedia.org/wiki/Solriamfetol

   Solriamfetol, sold under the brand name Sunosi, is a wakefulness-promoting medication used in the treatment of excessive sleepiness related to narcolepsy and sleep apnea. [1] [5] [6] It is taken by mouth. [1] Common side effects of solriamfetol include headache, nausea, anxiety, and trouble sleeping. [1]

4. Sleep apnea - Wikipedia

   en.wikipedia.org/wiki/Sleep_apnea

   There is limited evidence for medication, but 2012 AASM guidelines suggested that acetazolamide "may be considered" for the treatment of central sleep apnea; zolpidem and triazolam may also be considered for the treatment of central sleep apnea, [97] but "only if the patient does not have underlying risk factors for respiratory depression".

5. FDA approves Eli Lilly’s obesity medication for obstructive ...

   www.aol.com/fda-approves-eli-lilly-obesity...

   The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity -- the first medication ...

6. FDA Approves Weight Loss Medication Zepbound to Treat Sleep Apnea

   www.aol.com/lifestyle/fda-approves-weight-loss...

   The FDA also recommends that prescribed users reduce their caloric intake and increase their exercise

7. Obstructive sleep apnea - Wikipedia

   en.wikipedia.org/wiki/Obstructive_sleep_apnea

   A recent meta-analysis of 24 epidemiological studies on the prevalence of OSA in the general population aged 18 and older revealed that for ≥ 5 apnea events per hour, OSA prevalence ranged from 9% to 38%, specifically ranging from 13% to 33% in men and 6% to 19% in women, while in the population aged 65 and older, OSA prevalence was as high ...